for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

GlaxoSmithKline plc

GSK.L

Latest Trade

1,380.20GBp

Change

-16.40(-1.17%)

Volume

5,627,903

Today's Range

1,380.20

 - 

1,407.40

52 Week Range

1,328.19

 - 

1,857.00

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Pricing

Previous Close
1,396.60
Open
1,403.80
Volume
5,627,903
3M AVG Volume
129.57
Today's High
1,407.40
Today's Low
1,380.20
52 Week High
1,857.00
52 Week Low
1,328.19
Shares Out (MIL)
5,017.38
Market Cap (MIL)
70,744.99
Forward P/E
12.19
Dividend (Yield %)
7.02

Next Event

GlaxoSmithKline PLC to Discuss RSV Vaccines Data Call

Latest Developments

更多

GSK Says FDA Approves Nucala As Biologic Treatment For Hypereosinophilic Syndrome

BRIEF-Sanofi, GSK Sign Agreements With Canada For Up To 72 Million Doses Of Adjuvanted COVID-19 Vaccine

GlaxoSmithKline Gets CHMP Positive Opinion Recommending Nod Of Zejula's First-Line Monotherapy Maintenance Treatment

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About GlaxoSmithKline plc

GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. It has a portfolio of medicines in respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty products, and Classic and Established products. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, older people and travel vaccines.

Industry

Biotechnology & Drugs

Contact Info

G S K House, 980 Great West Road

TW8 9GS

United Kingdom

+44.20.80475000

https://www.gsk.com/

Executive Leadership

Jonathan Richard Symonds

Independent Non-Executive Chairman of the Board

Emma N. Walmsley

Chief Executive Officer, Executive Director

Iain James Mackay

Chief Financial Officer, Executive Director

Roger G. Connor

President - Vaccines

Brian McNamara

Chief Executive Officer - GSK Consumer Healthcare

Key Stats

2.44 mean rating - 27 analysts
Sell
Hold
Buy
Revenue (MM, GBP)

2017

30.2K

2018

30.8K

2019

33.8K

2020(E)

34.7K
EPS (GBp)

2017

111.800

2018

119.400

2019

123.900

2020(E)

115.951
Price To Earnings (TTM)
10.61
Price To Sales (TTM)
2.02
Price To Book (MRQ)
5.14
Price To Cash Flow (TTM)
8.91
Total Debt To Equity (MRQ)
233.13
LT Debt To Equity (MRQ)
189.26
Return on Investment (TTM)
15.87
Return on Equity (TTM)
9.92

Latest News

Latest News

UPDATE 1-GSK-J&J's long-acting HIV injection gets EU panel endorsement

GlaxoSmithKline Plc said an injection of its cabotegravir drug given every two months, in combination with Johnson & Johnson's rilpivirine, was recommended for approval to treat HIV infections by a panel of the European health regulator.

GSK's long-acting HIV injection endorsed by EU panel

GlaxoSmithKline Plc said on Friday an injection of its cabotegravir drug given every two months along with Johnson & Johnson's rilpivirine was recommended for approval to treat HIV infections by a panel of the European health regulator.

GSK to widen COVID-19 antibody treatment trial after safety clearance

GlaxoSmithKline and partner Vir Biotechnology will expand their trial of an experimental antibody to treat COVID-19 after initial use by a group of volunteers did not raise any safety concerns.

REFILE-GSK executive wary of human challenge trials for COVID-19 vaccine

GlaxoSmithKline Plc executive Thomas Breuer said on Tuesday he has "reservations" against human challenge trials as a tool for determining the effectiveness of COVID-19 vaccine candidates without a therapy for the infection.

UPDATE 2-Sanofi, GSK launch trial for COVID-19 protein-based vaccine

* Final testing stage expected to start in December (Recasts with detail, context)

GSK, partner Vir join race to find COVID-19 antibody treatment

GlaxoSmithKline and partner Vir Biotechnology have started testing their experimental antibody on early-stage COVID-19 patients, entering the race to find a winner in a promising class of antiviral drugs to combat the pandemic.

U.S. FDA approves GlaxoSmithKline's blood cancer drug

The U.S. Food and Drug Administration on Wednesday approved GlaxoSmithKline's experimental treatment for a common form of blood cancer.

UPDATE 1-U.S. to pay $2.1 bln to Sanofi, GSK, in COVID-19 vaccine deal

The U.S. government will pay $2.1 billion to Sanofi SA and GlaxoSmithKline Plc for COVID-19 vaccines to cover 50 million people and to underwrite the drugmakers' testing and manufacturing, the companies said on Friday.

REFILE-Sanofi, Glaxo advance talks to supply up to 300 mln COVID-19 vaccine doses to Europe -companies

Sanofi SA and GlaxoSmithKline Plc on Friday said they are in advanced discussions with the European Commission to supply up to 300 million doses of the drugmakers's experimental COVID-19 vaccine.

FACTBOX-U.S. pours billions into securing access to coronavirus vaccine candidates

As drugmakers race to develop vaccines and therapies for the novel coronavirus, the United States is rushing to secure access to them. The U.S. government has agreed to invest more than $7 billion in vaccines and has funded more than 30 projects, including for diagnostics...

U.S. to pay $2.1 bln to Sanofi, GSK, in COVID-19 vaccine deal

The U.S. government will pay $2.1 billion to Sanofi SA and GlaxoSmithKline Plc for COVID-19 vaccines to cover 50 million people and to underwrite the drug makers' testing and manufacturing, the companies said on Friday.

UPDATE 3-Britain secures 60 mln doses of Sanofi/GSK coronavirus vaccine

* For FACTBOX on vaccine race, click on (Updates with comparisons with other countries, GSK CEO comments)

Britain signs supply deal for 60 mln doses of Sanofi/GSK COVID-19 vaccine

Britain on Wednesday said it had signed a supply deal for up to 60 million doses of a possible COVID-19 vaccine being developed by Sanofi and GlaxoSmithKline, the fourth such deal it has struck.

UPDATE 1-GSK's blood cancer drug wins European panel thumbs-up

A panel of the European Medicines Agency (EMA) on Friday has recommended approving GlaxoSmithKline's experimental treatment for a common form of blood cancer, days after a similar nod from a U.S. Food and Drug Administration panel.

GSK's blood cancer drug wins European panel thumbs-up

GlaxoSmithKline's experimental treatment for a common form of blood cancer won marketing approval from a European Medicines Agency (EMA) panel on Friday.

London stocks gain on vaccine hopes, GlaxoSmithKline boost

London-listed shares rose on Wednesday as signs of progress in developing a COVID-19 vaccine bolstered hopes of a swift post-pandemic economic rebound, while GlaxoSmithKline gained after a U.S. health panel voted in favour of its blood cancer drug.

UPDATE 1-FDA panel votes in favor of approving GSK's multiple myeloma drug

An independent panel to the U.S. Food and Drug Administration on Tuesday voted in favor of approving GlaxoSmithKline's experimental treatment for a common form of blood cancer, saying the benefits of the treatment outweigh the risks.

FDA panel votes in favor of approving GSK's multiple myeloma drug

An independent panel to the U.S. Food and Drug Administration on Tuesday voted in favor of approving GlaxoSmithKline's experimental treatment for a common form of blood cancer, saying the benefits of the treatment outweigh the risks.

UPDATE 1-FDA unclear if benefits of GSK multiple myeloma drug outweigh risks

The U.S. Food and Drug Administration said on Friday it was unclear whether the benefits of GlaxoSmithKline's experimental treatment for a common form of blood cancer outweigh the risks ahead of a review of a side-effect which affects the eyes.

FDA says to review side effect of GSK's multiple myeloma drug

The U.S. Food and Drug Administration on Friday said it would review GlaxoSmithKline's experimental treatment for multiple myeloma, a common form of blood cancer, for a reported side-effect which affects the eyes of patients.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up